

Definition of Risk Groups in Oral Cavity Squamous Cell Carcinoma Patients and Prediction of Their Outcomes by Using ^{18}F -FDG PET/CT

Thesis

Submitted for the partial fulfillment of M.D. degree
in nuclear medicine

By

Yasser Gaber Ali

Assistant Lecturer

South Egypt Cancer Institute – Assiut University

Under Supervision of

Professor Dr. Hosna Moustafa

Professor of Nuclear Medicine

Faculty of Medicine - Cairo University

Professor Dr. Tzu-Chen Yen

Professor and Chairperson of Nuclear Medicine Department

Chang Gung Medical College and University - Taiwan

Dr. Haitham Fouad Abdel-Hameed

Lecturer of Nuclear Medicine

Faculty of Medicine - Cairo University

Faculty of Medicine

Cairo University

2011

بسم الله الرحمن الرحيم

اقْرَأْ بِاسْمِ رَبِّكَ الَّذِي خَلَقَ * خَلَقَ الْإِنْسَانَ مِنْ عَلَقٍ * اقْرَأْ

وَرَبُّكَ الْأَكْرَمُ * الَّذِي عَلَّمَ بِالْقَلَمِ * عَلَّمَ الْإِنْسَانَ مَا لَمْ يَعْلَمْ *

صدق الله العظيم

سورة العلق، الآيات 1-5

Abstract

Post-operative radiotherapy (RT) or chemoradiation (CRT) is indicated in the presence of adverse features “*extracapsular nodal spread, positive margins, pT3 or pT4 primary, N2 or N3 nodal disease, selected pT2N0-N1 disease, nodal disease in levels IV or V, perineural invasion, vascular embolism*” The prognostic factors that may modify the outcome have been described as patient-related (*gender, age, smoking, drinking, chewing betel quid*), tumor-related (*site, stage, thickness, extracapsular spread, differentiation, perineural invasion, angiogenesis, human papilloma virus infection*), and treatment-related factors (*resection margin, adjuvant post-operative therapy, and cervical lymph node dissection*).

Key word

- OSCC- Tumor-Related - Treatment-Related- Patient-Related
SCC- VS

Acknowledgement

I would like to express my deepest and sincere gratitude to my professor Dr. Hosna Moustafa, professor of nuclear medicine, Cairo University. I am greatly indebted to her and no words in my humble dictionary can express my appreciation to her kind supervision, meticulous but targeted revision, continuous support, and enormous educational potential.

I am very grateful to Prof. Dr. Tzu-Chen Yen, professor and chairperson of nuclear medicine in Chang Gung Memorial Hospital, Taiwan. She gave me a great opportunity to be among her research team in such amazing and friendly environment in Taiwan. Indeed, I have learnt a lot from her, especially how to think, conduct and analyze a research work.

Also, I would like to thank Dr. Haytham Fouad for his uninterrupted encouragement and fruitful exchange of ideas.

Many thanks to Dr. Liao Chun-Ta, professor of otolaryngology & head and neck surgery in Chang Gung Memorial Hospital, for providing the clinical and follow-up data, in addition to his supportive corrections and advices, and to all my colleagues and friends in Taiwan who helped me throughout the 2 years I have spent there and to my family who are always trying their best to make my life easier.

Table of Contents

Acknowledgement	i
Table of Contents	ii
List of Figures	iv
List of Tables	vi
List of Abbreviations	vii
Introduction	1
Aim of the Work	3
Anatomy of the Oral Cavity	4
I. Lips	4
II. Oral Cavity Proper	5
Regional Lymph Nodes	12
I. Anatomical Considerations	12
II. AJCC Nodal Classification	13
Overview of Oral Cavity Carcinoma	16
Epidemiology of OSCC	16
Incidence	16
Risk Factors	17
Pathology of Oral Cavity Carcinoma	22
I. Precancerous Lesions of oral cavity	22
II. Squamous Cell Carcinoma (SCC)	26
III. Verrucous Carcinoma (VC)	30
Staging of the Lip and Oral Cavity Cancer	31
Diagnosis of OSCC	35
Treatment Outlines for OSCC	36
1. Lip	37
2. Floor of the mouth	38
3. Oral Tongue	38
4. Buccal Mucosa	39
5. Lower Gum	39
6. Retromolar Trigone	39
7. Upper Gum and Hard Palate	39
Prognostic Factors in Oral Cavity Carcinoma	40
I. Patient-Related Prognostic Factors:	40
II. Tumor-Related Prognostic Factors:	41
III. Treatment-Related Prognostic Factors:	45
PET Imaging	47
PET Radiopharmaceuticals	47
Normal PET Imaging	48
1. Oral Cavity and Lymphoid Tissues	49
2. Brown Fat and Skeletal Muscles	51
3. Laryngeal Uptake	53
4. Osseous Uptake	53
5. Orbits	54
6. Thyroid gland	54
7. Thymus	55
8. Salivary Glands	55
Limitations of FDG PET in Head and Neck Cancer	55

1. Physiologic FDG Uptake	55
2. Inadequate Scanner Resolution	55
3. Recent Surgery and Inflammatory Response	56
4. Effect of Radiation and Chemotherapy	56
5. Low FDG Avidity	57
6. PET/CT Artifacts	57
Qualitative and Quantitative Parameters from PET	60
I. Qualitative Assessment	60
II. Quantitative Assessment	61
III. Semi-quantitative Assessment	61
Clinical Role of FDG-PET in Oral Cavity Carcinoma	66
I. Staging	66
II. Restaging and Therapy Monitoring	70
III. Prognosis and Risk Stratification	72
The Role of Non-FDG Radiopharmaceuticals	76
Patients and Methods	78
Patients	78
PET/CT Imaging Protocol	78
Data Reading & Analysis	79
Calculation of Total Lesion Glycolysis (TLG)	81
Surgery and Adjuvant Therapy	81
Follow-up Protocol	82
Statistical Analysis	82
Results	84
1. Patients	84
2. PET/CT Scores and SUV	88
3. Choice of the Best Contouring Method	89
4. Total Lesion Glycolysis (TLG)	90
5. Association between SUV & TLG and Different Pathological Characteristics	90
6. Univariate Analyses	93
7. Multivariate Analyses	112
8. Risk Score	115
9. Risk Groups Based on ECS & $_{NSUV}$	118
Case Presentation	119
Case 1: Score 0-patient	119
Case 2: Score 1-patient (pN+)	120
Case 3: Score 2-patient (high NSUV & pN+)	121
Case 4: Score 3-patient with a survival of 34 months	122
Case 5: Score 3-patient with a survival of 21 months	123
Case 6: Score 3-patient with a survival of 15 months	124
Case 7: Patient with positive ECS and low nodal SUV	125
Case 8: Patient with positive ECS and high nodal SUV	126
Discussion	127
Conclusion and Recommendations	136
Summary	137
References	141
Arabic Summary	171

List of Figures

Figure 1: Anatomical sites and sub-sites of the oral cavity (20).....	4
Figure 2: Lateral view of the tongue showing extrinsic muscles and its nerves(24)	6
Figure 3: Diagram of lymph drainage of the tongue(24).....	7
Figure 4: Coronal section in the floor of the mouth (24).	8
Figure 5: Schematic diagram showing the deep spaces of the face on the right and some of their contents on the left (25).....	8
Figure 6: A coronal image through the cheek showing the mucosa, muscle, fat pad, masseter, and a cross-section of the tongue and floor of mouth (21).	10
Figure 7: Trans-oral view of the alveolar ridge, retromolar region, and mandible of the left side of the oral cavity (21).	10
Figure 8: Vestibule and gingivae of the mandible (27).	11
Figure 9: Lymph vessels and nodes of the head and neck(29)	13
Figure 10: Schematic diagram indicating the location of the lymph node levels in the neck (20). ..	15
Figure 11: Palatal lesion associated with reverse smoking. Note the crate-like ulcerated areas covered with fibrin (45).....	19
Figure 12: Oral leukoplakia: (A) Gross picture showing numerous lesions that have become virtually confluent. (B) Microscopic picture showing marked epithelial thickening and hyperkeratosis	23
Figure 13: Proliferative verrucous leukoplakia involving the buccal gingiva (4).....	24
Figure 14: Nicotine Stomatitis: Rough, white, fissured appearance of the hard and soft palate in a heavy pipe smoker.	25
Figure 15: Squamous cell carcinoma of the lateral tongue	26
Figure 16: Verrucous carcinoma. White, exophytic, warty mass of the maxillary alveolar ridge (22).	31
Figure 17: Methods of measuring tumor thickness.	43
Figure 18: Mechanism of FDG uptake.....	48
Figure 19: Normal PET/CT scan (121).	49
Figure 20: Midline sagittal view with different H. & N. structures (122).	50
Figure 21: Most prominent uptake in the sublingual glands and mylohyoid muscle insertions (122).	50
Figure 22: Uptake in the soft palate (122).	50
Figure 23: Left: Palatine tonsils uptake, Right: uptake in the pharyngeal tonsil (adenoids) (122)..	51
Figure 24: Focal uptake at insertion of muscles into the occipital bone. Uptake is also seen in the sternocleidomastoid muscles (SCM) and parotid glands (124).....	51
Figure 25: Asymmetric sternocleidomastoid muscle uptake. (A) Axial CT right sternocleidomastoid muscle (arrow). (B) Fused PET-CT scan localizes the FDG uptake to the right sternocleidomastoid muscle (arrow). Note also the symmetric FDG uptake within the prevertebral strap muscles (arrowheads) (126).	52
Figure 26: Asymmetric increased uptake in the muscles of mastication.	52
Figure 27: Physiologic uptake in the vocalis muscle, arytenoid muscles and symmetric vocal cord uptake (122, 126).	53
Figure 28: Axial view of FDG-PET showing periodontal/dental (127).	54
Figure 29: (A) Hypermetabolic thyroid adenoma at the left lobe; (B) Hürthle cell carcinoma at the right lobe (126).	54
Figure 30: Physiologic uptake in the parotid (A) and submandibular glands (B) (126).	55
Figure 31: Inflammatory FDG uptake at the site of tracheostomy.....	56

<i>Figure 32: Dental abscess in a patient with history of squamous cell carcinoma of the left side of the tongue base. (A) CT scan shows no abnormality in the alveolar ridge of maxilla (B) PET-CT scan shows a focal area of intense FDG uptake in the site of infected tooth (arrow) (130).</i>	56
Figure 33: CT attenuation artifact from an implantable catheter port.	58
<i>Figure 34: Truncation artifact</i>	59
Figure 35: The tumor subsites seen	84
Figure 36: The pattern of recurrence in the 45 patients who experienced treatment failure (percentages are given among the 45 patients).	87
Figure 37: A 65-year-old male with left buccal cancer. (A) Axial T1 post-contrast image showed enhancement in a small area (2.7 cm) of irregular mucosal thickening in the left buccal area. (B) Fused PET/CT images revealed low FDG uptake in that site (SUVmax 4.34) and accordingly was scored 0.	88
Figure 38: Scatter plots for (A) the relation between maximum pathologic axial diameter of the fixed primary tumor and the diameter derived from tumor delineation using absolute SUV value of 3, and (B) the relation between maximum diameter of the pathologic lymph nodes and the diameter derived from lymph node delineation using absolute SUV value of 2.5.	89
Figure 39: ROC analyses of T_{TLG} (A) and N_{TLG} (B) in relation to presence of ECS. The best cut-off values identified were 92.19 and 18.51, respectively. N_{TLG} was significantly more accurate than T_{TLG} for predicting ECS ($P < 0.001$).	90
Figure 40: Local control rate according to the primary tumor TLG	93
Figure 41: Local control rate according to the presence or absence of bone marrow invasion	93
Figure 42: Neck control rate according to the neck lymph nodal TLG	96
Figure 43: Neck control rate according to the histopathological differentiation.	96
Figure 44: Distant metastases free survival rate according to the primary tumor TLG.	99
Figure 45: Distant metastases free survival according to the presence or absence of extra-capsular spread in the neck lymph nodes of 126 patients with oral cavity cancer.	99
Figure 46: Disease free survival rate according to the primary tumor TLG.	102
Figure 47: Disease free survival rate according to the pathologic status of neck lymph nodes.	102
Figure 48: Disease specific survival rate according to the primary tumor TLG.	105
Figure 49: Disease specific survival according to the pathologic status of neck lymph nodes.	105
Figure 50: Overall survival rate according to the neck lymph nodal SUV.	108
Figure 51: Overall survival rate according to the pathologic status of neck lymph nodes.	108
Figure 52: Disease free survival rate according to the proposed risk score.	116
Figure 53: Disease specific survival rate according to the proposed risk score.	116
Figure 54: Distant metastases free survival rate according to nodal SUV in 40 patients with positive ECS.	118
Figure 55: Disease specific survival rate according to nodal SUV in 40 patients with positive ECS.	118

List of Tables

Table 1: Common $\beta+$ emitters of clinical importance (118).	47
Table 2: General Clinical Characteristics of the Study Participants	85
Table 3: General Pathological Characteristics of the Study Participants	86
Table 4: Relation of primary tumor T_{SUV} and T_{TLG} to different pathological characteristics	91
Table 5: Relation of nodal N_{SUV} and N_{TLG} to different pathological characteristics	92
Table 6: Univariate analysis of 3-year local control (LC) according to clinical characteristics, SUV and TLG.	94
Table 7: Univariate analysis of 3-year local control (LC) according to pathological characteristics.	95
Table 8: Univariate analysis of 3-year neck control (NC) according to clinical characteristics, SUV and TLG.	97
Table 9: Univariate analysis of 3-year neck control (NC) according to pathological characteristics.	98
Table 10: Univariate analysis of 3-year distant metastases free survival (DMFS) according to clinical characteristics, SUV and TLG.	100
Table 11: Univariate analysis of 3-year distant metastases free survival (DMFS) according to pathological characteristics.	101
Table 12: Univariate analysis of 3-year disease free survival (DFS) according to clinical characteristics, SUV and TLG.	103
Table 13: Univariate analysis of 3-year disease free survival (DFS) according to pathological characteristics.	104
Table 14: Univariate analysis of 3-year disease specific survival (DSS) according to clinical characteristics, SUV and TLG.	106
Table 15: Univariate analysis of 3-year disease specific survival (DSS) according to pathological characteristics.	107
Table 16: Univariate analysis of 3-year overall survival (OS) according to clinical characteristics, SUV and TLG.	109
Table 17: Univariate analysis of 3-year overall survival (OS) according to pathological characteristics.	110
Table 18: Univariate analyses of 3-year local control (LC), neck control (NC), distant metastases free survival (DMFS), disease free survival (DFS), disease specific survival (DSS) and overall survival (OS) according to clinical data, SUV, TLG, and pathological characteristics.	111
Table 19: Multivariate analysis of 3-year local primary tumor control (LC).	112
Table 20: Multivariate analysis of 3-year neck control (NC).	112
Table 21: Multivariate analysis of 3-year distant metastases free survival (DMFS).	113
Table 22: Multivariate analysis of 3-year disease free survival (DFS).	113
Table 23: Multivariate analysis of 3-year disease specific survival (DSS)	114
Table 24: Multivariate analysis of 3-year overall survival (OS).	114
Table 25: Multivariate analysis of 3-year disease free (DFS) and disease specific survival (DSS), according to the proposed risk score.	115
Table 26: Some of the characteristics of patients with score 3	117

List of Abbreviations

<i>AJCC</i>	American Joint Committee on Cancer
<i>AUC</i>	Area Under Curve
<i>CCRT</i>	Concomitant ChemoRadioTherapy
<i>CGMH</i>	Chang Gung Memorial Hospital
<i>CI</i>	Confidence Interval
<i>COX</i>	Cyclooxygenase
<i>CRT</i>	ChemoRadioTherapy
<i>CT</i>	Computed Tomography
<i>CWU</i>	Conventional Work-Up
<i>DFS</i>	Disease Free Survival
<i>DICOM</i>	Digital Imaging and Communications in Medicine
<i>DMFS</i>	Distant Metastases Free Survival
<i>DOD</i>	Died Of Disease “cancer death”
<i>DSS</i>	Disease Specific Survival
<i>ECS</i>	Extra-capsular Spread
<i>EORTC</i>	European Organisation for Research and Treatment of Cancer
<i>FDG</i>	Fluodeoxyglucose
<i>FLT</i>	Fluoromisonidazole
<i>FMISO</i>	Fluoromisonidazole
<i>FWHM</i>	Full Width at Half Maximum
<i>HIF</i>	Hypoxia Inducible Factor
<i>HNC</i>	Head and Neck Cancer
<i>HNSCC</i>	Head and Neck Squamous Cell Carcinoma
<i>HPV</i>	Human Papilloma Virus
<i>HR</i>	Hazards Ratio
<i>JD</i>	Jugulodigastric
<i>JD</i>	Jugulo-Digastric
<i>JO</i>	Jugulo-omohyoid
<i>LC</i>	Local Control
<i>LGI</i>	Larson Ginsberg Index
<i>LN</i>	Lymph Node
<i>LND</i>	Lymph Node Dissection
<i>MD</i>	Moderately-Differentiated
<i>MIC</i>	Molecular Imaging Center
<i>MRI</i>	Magnetic Resonance Imaging
<i>MS</i>	Masticator Space
<i>MTV</i>	Metabolic Tumor Volume
<i>MVA</i>	Multivariate Analyses
<i>NC</i>	Neck Control

NCCN	National Comprehensive Cancer Network
NER	No Evidence of Recurrence
ns	Not significant
$_N$SUV	Standardized Uptake Value of the Lymph Nodes
$_N$TLG	Total Lesion Glycolysis of Lymph Nodes
OL	Oral Leukoplakia
OS	Overall Survival
OSCC	Oral Squamous Cell Carcinoma
PD	Poorly-Differentiated
PET/CT	Positron Emission Tomography/Computed Tomography
PVE	Partial Volume Effect
RMT	Retromolar Trigone
ROC	Receiver Operating Characteristics
ROI	Region Of Interest
RT	Radiotherapy
RTOG	Radiation Therapy Oncology Group
S/B Ratio	Signal to Background Ratio
SCC	Squamous Cell Carcinoma
SCM	Sternocleidomastoid
SD	Standard Deviation
SIL	Squamous Intraepithelial Lesion
SOHND	Supra-Omohyoid Neck Dissection
SUV	Standardized Uptake Value
SUV_{avg}	Average Standardized Uptake Value
SUV_{lean}	Standardized Uptake Value normalized to Lean Body Mass
SUV_{max}	Maximum Standardized Uptake Value
SUV_{peak}	Peak Standardized Uptake Value
TLG	Total Lesion Glycolysis
TNM	Tumor, Node and Metastasis
$_T$SUV	Standardized Uptake Value of the Primary Tumor
$_T$TLG	Total Lesion Glycolysis of the Primary Tumor
UADT	Upper Aerodigestive Tract
US	Ultrasound
UVA	Univariate Analyses
VC	Verrucous Carcinoma
VEGF	Vascular Endothelial Growth Factor
VEGF	Vascular Endothelial Growth Factor
VOI	Volume Of Interest
WD	Well-Differentiated
WHO	World Health Organization

Introduction

Oral cancer is the eighth most common cancer worldwide, with epidemiologic variations between different geographic regions (1). The World Health Organization (WHO) expects a worldwide rising incidence in the next decades (2).

Surgery is the main stay for resectable oral squamous cell carcinoma (OSCC). Post-operative radiotherapy (RT) or chemoradiotherapy (CRT) is indicated in the presence of specific adverse features (3).

Numerous prognostic factors have been identified including clinical, anatomical and pathological risk factors; however, and in spite of the ready accessibility of the oral cavity to direct examination, these malignancies still often not detected until a late stage, and the survival rate for oral cancer has remained essentially unchanged over the past three decades (4).

The possibility of identifying novel prognostic factors in oral cancer may help in stratifying different risk groups and personalizing the cancer management process.

Recently, standardized uptake value (SUV), a simplified index of glucose uptake of the tumor measured from ^{18}F -fluorodeoxyglucose positron emission tomography/computed tomography (^{18}F -FDG PET/CT), has been strongly introduced as a possible prognostic factor in many cancers, including head and neck cancer (5-10). However, some drawbacks are inherent to the use of SUV, one of these drawbacks is being a single pixel value not reflecting the real tumor heterogeneity (11).

The concept of total lesion glycolysis (TLG) has been introduced by *Larson et al.* to study the change of glucose metabolism pre- and post-therapy (12). It was calculated as the product of tumor volume from PET/CT and the average SUV within this volume.

Their results set the stage for other groups at Memorial Sloan-Kettering Cancer Center to study TLG among other parameters in evaluation of lung cancer after radiation treatment (13) and to predict long-term outcomes in patients with rectal cancer (14). They found good correlation between TLG with treatment response and outcomes. TLG also was investigated in patients with esophageal cancer (15, 16), soft tissue sarcoma (17), osteosarcoma (18) and melanoma (19), with encouraging results.

The potential prognostic role of baseline SUV and TLG measured at the primary tumor and neck lymph nodes has not been studied in patients with OSCC.

Aim of the Work

To evaluate the potential prognostic role of presurgical standardized uptake value (SUV) and total lesion glycolysis (TLG), measured from FDG PET/CT at the primary tumor and neck lymph nodes, in identifying different risk groups of oral cavity squamous cell carcinoma (OSCC) and predicting their outcomes.

Anatomy of the Oral Cavity

Oral cancer can be divided into two main categories: one arising in the oropharynx and one arising in the oral cavity. The latter, *which is the focus of this review*, is subdivided into oral cavity proper and lip vermilion (**Figure 1**) (4).




Figure 1: Anatomical sites and sub-sites of the oral cavity (20)

I. Lips

The lip begins at the junction of the vermillion border, which marks the beginning of the red transitional zone between the skin and the mucous membrane of the lip, and includes only the vermillion surface (*that portion of the lip that comes into contact with the opposing lip*). It is well defined into an upper and lower lip joined at the commissures of the mouth (20).

Beneath the lip skin is a layer of subcutaneous tissue with many muscles, nerves, and vessels. This subcutaneous tissue lies just superficial to the orbicularis oris muscle, which forms the main bulk of the lips. Deep to that muscle are numerous labial salivary glands, each with a small duct penetrating the mucosal membrane. The